ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None20232022202120202019201820172016 May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections May 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 2, 2023 Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 April 20, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology April 12, 2023 Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer April 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 8, 2023 Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates March 7, 2023 Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society March 3, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
Year None20232022202120202019201820172016 May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections May 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 2, 2023 Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 April 20, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology April 12, 2023 Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer April 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 8, 2023 Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates March 7, 2023 Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society March 3, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
May 2, 2023 Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
April 20, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
March 8, 2023 Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
March 7, 2023 Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society